Condition
    Strong Evidence
    Effectiveness 3/5

    Digestive Enzymes for SIBO (Small Intestinal Bacterial Overgrowth)

    Digestive enzymes are not a treatment for small intestinal bacterial overgrowth and may not address the underlying motility problem.

    Overview

    Digestive enzymes are not a treatment for small intestinal bacterial overgrowth and may not address the underlying motility problem.

    Verdict

    Insufficient evidence

    How It Works

    Reducing undigested substrate could theoretically limit bacterial fermentation in the small bowel, but enzymes do not affect bacterial load or motility.

    Dosing & Protocol

    Typical dose

    Recommended dose
    No established dose — evidence is insufficient. Digestive enzymes have not been shown to treat SIBO at any dose; treatment is antibiotic (e.g. rifaximin) or elemental diet, prescribed by a clinician.
    Expected timeframe
    Not established — no reduction in overgrowth demonstrated

    Protocol

    dose
    Not established for SIBO
    form
    n/a — enzymes are not a SIBO treatment
    steps
    Evidence is insufficient: no controlled trial supports digestive enzymes as a treatment for small intestinal bacterial overgrowth,Get a diagnosis — lactulose or glucose breath testing, and exclusion of coeliac disease, pancreatic insufficiency and IBD,Established treatment is clinician-directed: rifaximin or another targeted antibiotic, sometimes an elemental diet, followed by treating the underlying motility or structural cause,Enzymes may reduce some meal-related gas symptomatically, but they do not reduce bacterial overgrowth,Do not use enzymes as a substitute for diagnosis and treatment
    timing
    n/a
    duration
    n/a

    Evidence

    What the studies say

    No randomised trial evaluates digestive enzymes in SIBO. Standard evidence-based management centres on antibiotics such as rifaximin, dietary approaches and prokinetics.

    No studies are yet linked to both Digestive Enzymes and SIBO (Small Intestinal Bacterial Overgrowth).

    Safety

    Caveats

    Insufficient evidence. Self-treating delays diagnosis of coeliac disease, pancreatic insufficiency, IBD and motility disorders. Untreated SIBO can cause B12 deficiency and fat malabsorption. Alpha-galactosidase is contraindicated in galactosaemia. Seek care for weight loss, bleeding or anaemia.

    Less likely to help if

    Everyone with true SIBO — enzymes do not address bacterial overgrowth.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.